Clinical trials: Ankylosing Spondylitis
Ankylosing Spondylitis
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
This study of adalimumab (Humira) will be conducted to clarify the following with regard to the treatment of ankylosing spondylitis with this drug: Unknown adverse drug reactions (especially important adverse drug reactions)…
- Trial name
- NCT01329380
- Where
- 194 sites in Japan
- Volunteers
- 403 people
- Sponsor
- AbbVie
Nonradiographic Axial Spondylitis, Ankylosing
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy and safety of ustekinumab in adult participants with active nonradiographic axial spondyloarthritis (nr-AxSpA) measured by the reduction in signs and symptoms of nonradiographic…
- Trial name
- NCT02407223
- Testing
- Group 2: Ustekinumab 45 mg, Group 3: Ustekinumab 90 mg
- Where
- 90 sites in Argentina, Australia and 12 more
- Volunteers
- 356 people
- Sponsor
- Janssen Research & Development, LLC
Ankylosing Spondylitis
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
This is a multi-center, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of ENIA11 in patients with ankylosing spondylitis.
- Trial name
- NCT02685904
- Testing
- ENIA11
- Where
- 6 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Mycenax Biotech Inc.
Axial Spondyloarthritis
A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life
The primary purpose is to assess the effectiveness of certolizumab pegol in patients with axial spondyloarthritis under routine clinical practice.
- Trial name
- CIMAX (NCT02354105)
- Where
- 100 sites in Belgium, Germany and 4 more
- Volunteers
- 680 people
- Sponsor
- UCB Biopharma S.P.R.L.
Spondylitis, Ankylosing
Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)
This two-part study was to evaluate the effect of golimumab (SCH 900259, MK-8259) in participants with active axial spondyloarthritis (axial SpA).
- Trial name
- GO-AHEAD (NCT01453725)
- Testing
- Golimumab
- Volunteers
- 198 people
- Sponsor
- Merck Sharp & Dohme LLC
Ankylosing Spondylitis
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
The objective of this study is to determine the difference in the annual incidence rate of uveitis attacks in participants with ankylosing spondylitis (AS) before start initial anti-TNF therapy and after treatment with golimumab…
- Trial name
- GO-EASY (NCT01668004)
- Testing
- Golimumab
- Volunteers
- 101 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
This was a prospective mono-country, multi-center study of the frequency of extra-axial manifestations (EAMs) in Ankylosing Spondylitis (AS) participants treated with adalimumab in routine clinical practice.
- Trial name
- AS PMOS (NCT02333383)
- Testing
- Adalimumab
- Volunteers
- 201 people
- Sponsor
- AbbVie
Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative
Tracking Biologics Along the Silk Road
The objective of this study is to explore and describe the disease characteristics, treatment and outcomes of participants with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's Disease or ulcerative…
- Trial name
- HARIR (NCT03006198)
- Where
- 8 sites in Algeria, Egypt and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Ankylosing Spondylitis, Psoriatic Arthritis
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.
- Trial name
- SPACTIVE (NCT01845818)
- Volunteers
- 183 people
- Sponsor
- AbbVie
Spondylitis, Ankylosing
16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Trial name
- MEASURE 3 (NCT02008916)
- Testing
- Secukinumab
- Where
- 57 sites in United States, Belgium and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Degenerative Joint Disease, Congenital Deformity
Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
STUDY OBJECTIVES: To demonstrate equivalent clinical and radiologic outcomes as "gold standard" (Autologous Bone Graft) in a representative clinical model (hindfoot fusions) STUDY HYPOTHESIS: Augment® Injectable is an equivalent…
- Conditions
- Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis
- Trial name
- NCT01305356
- Testing
- Augment® Injectable Bone Graft, Autologous bone graft
- Where
- 25 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- BioMimetic Therapeutics
Ankylosing Spondylitis
Defining Remission With Etanercept in AS in Real Life Clinical Practice
Determine which remission criterion at Month 6 predicts remission at Month 12 the best.
- Trial name
- REACH AS (NCT02202850)
- Testing
- etanercept
- Where
- 29 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Spondyloarthropathies
Benepali® PEN Patient Satisfaction Survey
The main aim of this study is to ascertain general satisfaction among participants with rheumatic diseases with day-to-day use of the Benepali® prefilled pen by means of a standardised participant questionnaire.
- Trial name
- NCT03327454
- Testing
- Benepali
- Where
- 38 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Biogen
Rheumatoid Arthritis, Ankylosing Spondylitis
Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World
TNF- α receptor inhibitors have been used widely in practice and are well developed in China. Anbainuo is a bio-similar recombinant TNF-α receptor: IgG Fc fusion protein, approved in 2015.
- Trial name
- NCT03636984
- Testing
- recombinant TNF-α receptor: IgG Fc fusion protein
- Volunteers
- 1,000 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Ankylosing Spondylitis
A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with active Ankylosing Spondylitis (AS). A total of approximately 100 subjects will be randomized to one of 2 treatment arms in a 1:1 ratio: oral…
- Trial name
- TORTUGA (NCT03117270)
- Testing
- filgotinib
- Where
- 30 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 116 people
- Sponsor
- Lakefront Biotherapeutics NV
AS
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory…
- Trial name
- NCT02893254
- Testing
- IBI303, Adalimumab
- Volunteers
- 438 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Axial Spondyloarthritis
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
The objective of this multicenter, randomized, double-blind study was to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week SC in maintaining remission in…
- Trial name
- NCT01808118
- Testing
- adalimumab
- Volunteers
- 673 people
- Sponsor
- AbbVie
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Ankylosing Spondylitis
Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis
BCD-055-2 is international multi-center comparative double-blind randomized clinical trial to evaluate efficacy and safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in patients with ankylosing spondylitis.
- Trial name
- NCT02762812
- Testing
- BCD-055, Remicade®
- Where
- Russia
- Volunteers
- 199 people
- Sponsor
- Biocad